TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-reported abstinence 12 weeks postpartum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Requirement of additional analgesics intraoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Block failure (conversion to general anaesthesia)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of TETA 4HCL and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EEG compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colonisation with the challenge C. difficile strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Infection with the challenge C. difficile strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Assessment of Constipation -Symptom Questionnaire (PAC-SYM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Assessment of constipation quality of life questionnaire (PAC-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in toe pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in the toe-brachial index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in the ankle-brachial index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intention to receive the HIV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visualization of the target vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neutralising antibody levels to HPV16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralising antibody levels to HPV18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onychomycosis severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: relative level of LINC01844
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of allergic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: State-Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eye Axial Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ATTR-CM in patients with HFpEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of PrimeC
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of LIB-01 in treating erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in acceptability scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion completed a visit with a Primary Care provider
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion receiving an order for LDCT lung cancer screen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion completing LDCT lung cancer screen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in the revised ALS Functional Rating Score (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knowledge of burn and scald nursing care scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in motivation and attitude toward learning and personal self-efficacy scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported measure of satisfaction of learning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in FeO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fe.sevo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mononuclear cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Atrophy and necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pyknotic nucleus assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in test scores before and after physical exercise training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of patient adherence to the program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Unplanned hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Sexual quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: E2 and P4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Daily Average Pain Score (DAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in Forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in severity of xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in unstimulated salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stimulated salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of perinatal/neonatal morbidity/mortality
Endpoint domain: Mortality/survival
Primary endpoint: Blood flow through the popliteal, brachial, and carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occurrence of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Neurological repercussions
Endpoint domain: Adverse events/effects
Primary endpoint: Intracranial aneurysm growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intracranial aneurysm rupture
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean concentration of anti-spike SARS-CoV-2 IgG antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in treatment delay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of postural balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of muscular activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intestinal spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Response Rate (ORR) of hemophagocytic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Suppression (HIV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Retention in HIV care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Antiretroviral therapy adherence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Hyperhidrosis Disease Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency expression of CD226 at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency expression of CD226 3 weeks after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phenotype of expression of CD226 at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phenotype of expression of CD226 3 weeks after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IGT PDR cut-off level for liver graft use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with a success rate of >50% in pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in pain intensity by VAS (Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in pain intensity by DN4 questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo Handicap Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of subjects with at least 1 treatment-emergent AE or SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects discontinuing study drug due to pulmonary edema and/or major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Multidimensional Pain Inventory (MPI)-SCI average activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor recovery as measured by EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor recovery as measured by dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decisional Conflict Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of moderate to vigorous physical activity (MVPA) per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes risk based on HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of new onset target vessel myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of target vessel revascularization of failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of target lesion revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in vital sign measurements: systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute post-treatment toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of technical problems with NIRS monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parental noncompliance with PHBQ reporting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Electromyographic Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional reorganization of the attentional network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Comprehensive Score for Financial Toxicity (COST)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median nerve cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dual-task step frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual-task cognitive performance accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline enjoyment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positivity rate for monogenic obesity diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Range of Motion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of optimal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI activation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Concentration (Cmax) of Lebrikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Lebrikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulant abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migration of device to bladder
Endpoint domain: Adverse events/effects
Primary endpoint: serum levels of janus kinase 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of Serology-confirmed SARS-CoV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: REEDA Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative stress level of renal vasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of clinical manifestations of malignant hyperthermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of gripping task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardization of samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Physician-reported acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Kinetics and kinematics of the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Memory Based Everyday Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Memory Based Compensation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nightmare frequency and severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Consented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants that complete the Intervention as prescribed (Adherence)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Euclidean distance from the vector describing subject-specific, simulated gravitational collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pooled intermuscular coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musical difficulties during and after cancer treatments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratio of kidney and tumour absorbed doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median maximum tolerated dose in mg/day
Endpoint domain: Physiological/clinical
Primary endpoint: Wheelchair Lead Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Continued usage with satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability and safety of psilocybin with risperidone
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Level of Anti-RBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of diagnostic confidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on Montreal Cognitive Assessment test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VTE-KAP questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical difficulties
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric mean titers of neutralizing antibody against Beta variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers of neutralizing antibody against Delta variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers of neutralizing antibody against Omicron variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Healthy Eating Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Dose Limiting Toxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: tendon stiffness level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in growth of candida in the gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Timed sit and stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel Activities of Daily Living Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physician discharge order time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of hypotension event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of the Preemie system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of the Preemie system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using Preemie system for breast milk fortification
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fetal Base excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of intra-pulmonary ventilation volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: whether the tumor was completely removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cerebral infarctions (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Significant carotid artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Temporomandibular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Multisite pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ΔΔQTc prolongation of 10 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ΔΔJ-TpeakC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Knee Society Score (KSS) equal or greater than Good (score ≥ 70)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised Nottingham Sensory Assessment (Somatosensory Impairments)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of viable bacteria detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric Mean Titers (GMTs) for HPV Types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breast milk supply rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the level of asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody seroconversion rate against SARS-CoV-2 neutralising antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of local and systemic solicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of unsolicited AEs, SAEs and AESIs
Endpoint domain: Adverse events/effects
Primary endpoint: Pain change assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiemetic use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hemodynamic response in prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Report of Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year overall survival rate of Participants
Endpoint domain: Mortality/survival
Primary endpoint: disease-free survival of Participants
Endpoint domain: Mortality/survival
Primary endpoint: progression-free survival of Participants
Endpoint domain: Mortality/survival